Sutureless transconjunctival 20 g pars plana vitrectomy

Article

Sutureless transconjunctival 20 g ppv is, according to this study, an ideal technique for all vitreoretinal surgeries.

Key Points

Minimally invasive techniques have been introduced across virtually the whole spectrum of surgery. In ophthalmology sutureless operating techniques in cataract surgery and recently in vitrectomy offer less postoperative inflammation, shorter intraoperative and recovery time. In this article is reported the evaluation, feasibility and safety of the Sutureless Transconjuctival 20 Gauge Vitrectomy (20 STV).

How the technique works

Subconjunctival antibiotics and corticosteroids are used at the end of the procedure. Few fluid filled eyes had minimal leakage of fluid. Eyes with air or gas fill are less likely to be hypotonous at the end of theoperation. Eyes that ended up with silicone oil had no leakage at all due to higher viscosity of the oil. The pressure of the eyes at the end of the operation was either normal or slightly low. In cases where hypotony was noticed additional air or fluid was injected through pars plana with a 27 gauge needle. Slight chemosis occurred in a few cases.

Related Videos
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Giulia Corradetti, MD, discusses her presentation "Functional Microperimetric Correlates of OCT Structures Features in Intermediate AMD"
At this year's ARVO meeting, Paolo Silva, MD, presented data on Protocol AA on behalf of the DRCR Retina Network
Baruch Kuppermann, MD, PhD
At this year's ARVO meeting, Qinqin Zhang, PhD, presented a poster titled "A unified deep learning model for geographic atrophy segmentation: Adaptable to SS-OCT and SD-OCT data with multiple scan patterns."
Ash Abbey, MD, shares 36-month data from the GALE study of pegcetacoplan
© 2024 MJH Life Sciences

All rights reserved.